Holland & Knight advised Savara on the offering. Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $100 million...
Savara’s $100 Million Common Stock Offering
Savara Inc.’s $130 Million Public Offering
Wilson Sonsini Goodrich & Rosati advised Savara Inc. on the deal. Savara Inc., an orphan lung disease company, announced the closing of an underwritten public offering...